Publications by authors named "Alan Solinger"

Claim this Profile
R
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, Alan Solinger

Ann Rheum Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
James G Krueger, Laura K Ferris, Alan Menter, Frank Wagner, Alexander White, Alan Solinger

J Allergy Clin Immunol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared decision-making at end-of-life is aided by graphical trending of illness severity.
David B Bittleman, Alan B Solinger, G Duncan Finlay

BMJ Case Rep· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risks of mortality associated with common laboratory tests: a novel, simple and meaningful way to set decision limits from data available in the Electronic Medical Record.
Alan B Solinger, Steven I Rothman

Clin Chem Lab Med· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placing clinical variables on a common linear scale of empirically based risk as a step towards construction of a general patient acuity score from the electronic health record: a modelling study.
Steven I Rothman, Michael J Rothman, Alan B Solinger

BMJ Open· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications and validity of nursing assessments: a longitudinal measure of patient condition from analysis of the Electronic Medical Record.
Michael J Rothman, Alan B Solinger, Steven I Rothman, G Duncan Finlay

BMJ Open· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.
Claudia Cavelti-Weder, Andrea Babians-Brunner, Cornelia Keller, Marc A Stahel, Malaika Kurz-Levin, Alan M Solinger

Diabetes Care· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Ahmet Gül, Ilknur Tugal-Tutkun, Charles A Dinarello, Leonid Reznikov, Bahar Artim Esen, Alan Solinger

Ann Rheum Dis· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of IL-1beta improves fatigue in type 2 diabetes.
Claudia Cavelti-Weder, Romana Furrer, Cornelia Keller, Andrea Babians-Brunner, Alan M Solinger

Diabetes Care· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-1 family nomenclature.
Charles Dinarello, William Arend, John Sims, Dirk Smith, Hal Blumberg, Alan Solinger

Nat Immunol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etanercept in adult patients with early onset ankylosing spondylitis.
Robert D Inman, Daniel O Clegg, John C Davis, James B Whitmore, Alan Solinger

J Rheumatol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
Daniel E Furst, Roy Fleischmann, Elliott Kopp, Michael Schiff, Carl Edwards, Alan Solinger

J Rheumatol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manipulation under anesthesia: a report of four cases.
Edward Cremata, Stephen Collins, William Clauson, Alan B Solinger, Edward S Roberts

J Manipulative Physiol Ther· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
Daniel J Lovell, Suzanne L Bowyer, Alan M Solinger

Arthritis Rheum· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.
Michael H Schiff, Gino DiVittorio, John Tesser, Roy Fleischmann, Joy Schechtman, Alan M Solinger

Arthritis Rheum· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
John Tesser, Roy Fleischmann, Robin Dore, Ralph Bennett, Alan Solinger

J Rheumatol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatic manifestations of human immunodeficiency virus.
Alan M Solinger

Curr Rheumatol Rep· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A reassessment of normal cervical range of motion.
Charles A Lantz, Geoffrey Klein, Jasper Chen, Anne Mannion, Alan B Solinger

Spine (Phila Pa 1976)· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis